Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 322

1.

Compliance with needle-use declarations at two Olympic Winter Games: Sochi (2014) and PyeongChang (2018).

Schobersberger W, Blank C, Budgett R, Pipe A, Stuart MC.

Br J Sports Med. 2019 Jun 15. pii: bjsports-2018-100342. doi: 10.1136/bjsports-2018-100342. [Epub ahead of print]

PMID:
31203198
2.

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suciu S, Robert C.

Eur J Cancer. 2019 Jun 11;116:148-157. doi: 10.1016/j.ejca.2019.05.020. [Epub ahead of print]

PMID:
31200321
3.

Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors.

Rogiers A, Boekhout A, Schwarze JK, Awada G, Blank CU, Neyns B.

J Oncol. 2019 Apr 28;2019:5269062. doi: 10.1155/2019/5269062. eCollection 2019. Review.

4.

Combining checkpoint inhibition and targeted therapy in melanoma.

Rozeman EA, Blank CU.

Nat Med. 2019 Jun;25(6):879-882. doi: 10.1038/s41591-019-0482-7. No abstract available.

PMID:
31171877
5.

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O, Sikorska K, Eriksson H, Broeks A, van Thienen JV, Guminski AD, Acosta AT, Ter Meulen S, Koenen AM, Bosch LJW, Shannon K, Pronk LM, Gonzalez M, Ch'ng S, Grijpink-Ongering LG, Stretch J, Heijmink S, van Tinteren H, Haanen JBAG, Nieweg OE, Klop WMC, Zuur CL, Saw RPM, van Houdt WJ, Peeper DS, Spillane AJ, Hansson J, Schumacher TN, Long GV, Blank CU.

Lancet Oncol. 2019 May 31. pii: S1470-2045(19)30151-2. doi: 10.1016/S1470-2045(19)30151-2. [Epub ahead of print]

PMID:
31160251
6.

Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program.

Bisschop C, Wind TT, Blank CU, Koornstra RHT, Kapiteijn E, Van den Eertwegh AJM, De Groot JWB, Jalving M, Hospers GAP.

J Immunother. 2019 Jul/Aug;42(6):208-214. doi: 10.1097/CJI.0000000000000271.

PMID:
31145233
7.

Does Physical Activity during Alpine Vacations increase Tourists' Well-Being?

Schlemmer P, Blank C, Schnitzer M.

Int J Environ Res Public Health. 2019 May 15;16(10). pii: E1707. doi: 10.3390/ijerph16101707.

8.

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M.

Nat Med. 2019 Jun;25(6):920-928. doi: 10.1038/s41591-019-0432-4. Epub 2019 May 13.

PMID:
31086347
9.

Feasibility of Ski Mountaineering for Patients Following a Total Knee Arthroplasty: A Descriptive Field Study.

Haslinger S, Huber D, Morawetz D, Blank C, Prossegger J, Dünnwald T, Koller A, Fink C, Hartl A, Schobersberger W.

Int J Environ Res Public Health. 2019 May 6;16(9). pii: E1582. doi: 10.3390/ijerph16091582.

10.

Colonization, Baker's law, and the evolution of gynodioecy in Hawaii: implications from a study of Lycium carolinianum.

Miller JS, Blank CM, Levin RA.

Am J Bot. 2019 May;106(5):733-743. doi: 10.1002/ajb2.1279. Epub 2019 May 1.

PMID:
31042317
11.

The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment.

O'Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MWL.

Clin Cancer Res. 2019 Apr 30. doi: 10.1158/1078-0432.CCR-18-2641. [Epub ahead of print] Review.

PMID:
31040150
12.

A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX).

Bex A, van Thienen JV, Schrier M, Graafland N, Kuusk T, Hendricksen K, Lagerveld B, Zondervan P, van Moorselaar JA, Blank C, Wilgenbos S, Haanen J.

Future Oncol. 2019 Apr 26. doi: 10.2217/fon-2019-0111. [Epub ahead of print]

PMID:
31023100
13.

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma.

van Herpen CML, Agarwala SS, Hauschild A, Berking C, Beck JT, Schadendorf D, Jansen R, Queirolo P, Ascierto PA, Blank CU, Heinrich MC, Pal RR, Derti A, Antona V, Nauwelaerts H, Zubel A, Dummer R.

Oncotarget. 2019 Mar 5;10(19):1850-1859. doi: 10.18632/oncotarget.26753. eCollection 2019 Mar 5.

14.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejbergs L, Schmidt H, van Thienen JV, Haanen JBAG, Tiainen L, Svane IM, Mäkelä S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, Long GV, Atkinson V, Blank CU, Neyns B.

Ann Oncol. 2019 Mar 28. pii: mdz110. doi: 10.1093/annonc/mdz110. [Epub ahead of print]

PMID:
30923820
15.

Sex-Related Differences After a Single Bout of Maximal Eccentric Exercise in Response to Acute Effects: A Systematic Review and Meta-analysis.

Morawetz D, Blank C, Koller A, Arvandi M, Siebert U, Schobersberger W.

J Strength Cond Res. 2019 Mar 15. doi: 10.1519/JSC.0000000000002867. [Epub ahead of print]

PMID:
30908366
16.

Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers.

Trebeschi S, Drago SG, Birkbak NJ, Kurilova I, Cǎlin AM, Pizzi AD, Lalezari F, Lambregts DMJ, Rohaan M, Parmar C, Hartemink KJ, Swanton C, Haanen JBAG, Blank CU, Smit EF, Beets-Tan RGH, Aerts HJWL.

Ann Oncol. 2019 Mar 21. pii: mdz108. doi: 10.1093/annonc/mdz108. [Epub ahead of print]

PMID:
30895304
17.

Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma.

Schermers B, Franke V, Rozeman EA, van de Wiel BA, Bruining A, Wouters MW, van Houdt WJ, Ten Haken B, Muller SH, Bierman C, Ruers TJM, Blank CU, van Akkooi ACJ.

Br J Surg. 2019 Apr;106(5):519-522. doi: 10.1002/bjs.11168. Epub 2019 Mar 18.

PMID:
30882901
18.

Dedicated Ultrasound Speckle Tracking for Quantitative Analysis of Uterine Motion Outside Pregnancy.

Sammali F, Kuijsters NPM, Huang Y, Blank C, Rabotti C, Schoot BC, Mischi M.

IEEE Trans Ultrason Ferroelectr Freq Control. 2019 Mar;66(3):581-590. doi: 10.1109/TUFFC.2018.2867098.

PMID:
30872213
19.

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.

Schilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, Kähler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA, Goldinger SM, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B.

Cancer Immunol Immunother. 2019 May;68(5):765-772. doi: 10.1007/s00262-019-02311-1. Epub 2019 Feb 26.

PMID:
30806748
20.

A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma.

Wind TT, Jalving M, de Haan JJ, de Vries EGE, van Vugt MATM, Reijngoud DJ, van Rijn RS, Haanen JBAG, Blank CU, Hospers GAP, Fehrmann RSN.

Oncoimmunology. 2019 Jan 3;8(3):1558664. doi: 10.1080/2162402X.2018.1558664. eCollection 2019.

21.

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.

Liu J, Rozeman EA, O'Donnell JS, Allen S, Fanchi L, Smyth MJ, Blank CU, Teng MWL.

Oncoimmunology. 2018 Nov 22;8(2):e1546068. doi: 10.1080/2162402X.2018.1546068. eCollection 2019.

PMID:
30713806
22.

Prediction of implantation after blastocyst transfer in in vitro fertilization: a machine-learning perspective.

Blank C, Wildeboer RR, DeCroo I, Tilleman K, Weyers B, de Sutter P, Mischi M, Schoot BC.

Fertil Steril. 2019 Feb;111(2):318-326. doi: 10.1016/j.fertnstert.2018.10.030. Epub 2019 Jan 2.

PMID:
30611557
23.

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma.

Li H, van der Leun AM, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi ACJ, van den Braber M, Rozeman EA, Haanen JBAG, Blank CU, Horlings HM, David E, Baran Y, Bercovich A, Lifshitz A, Schumacher TN, Tanay A, Amit I.

Cell. 2019 Feb 7;176(4):775-789.e18. doi: 10.1016/j.cell.2018.11.043. Epub 2018 Dec 27.

PMID:
30595452
24.

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA, Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, Hospers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W Jr, Donica M, Makrutzki M, Blank C.

Eur J Cancer. 2019 Jan;107:175-185. doi: 10.1016/j.ejca.2018.11.018. Epub 2018 Dec 20.

PMID:
30580112
25.

Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy.

Batzner A, Pfeiffer B, Neugebauer A, Aicha D, Blank C, Seggewiss H.

J Am Coll Cardiol. 2018 Dec 18;72(24):3087-3094. doi: 10.1016/j.jacc.2018.09.064.

PMID:
30545446
26.

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van Velthoven R, Del Pilar Laguna M, Wood L, van Melick HHE, Aarts MJ, Lattouf JB, Powles T, de Jong IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen J.

JAMA Oncol. 2018 Dec 13. doi: 10.1001/jamaoncol.2018.5543. [Epub ahead of print] Erratum in: JAMA Oncol. 2019 Feb 1;5(2):271.

PMID:
30543350
27.

Effects of Recreational Ski Mountaineering on Cumulative Muscle Fatigue - A Longitudinal Trial.

Haslinger S, Blank C, Morawetz D, Koller A, Dünnwald T, Berger S, Schlickum N, Schobersberger W.

Front Physiol. 2018 Nov 27;9:1687. doi: 10.3389/fphys.2018.01687. eCollection 2018.

28.

Remission of psoriasis during treatment with sorafenib.

van Kester MS, Luelmo SAC, Vermeer MH, Blank C, van Doorn R.

JAAD Case Rep. 2018 Nov 14;4(10):1065-1067. doi: 10.1016/j.jdcr.2018.09.009. eCollection 2018 Nov. No abstract available.

29.

Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.

Brummer C, Faerber S, Bruss C, Blank C, Lacroix R, Haferkamp S, Herr W, Kreutz M, Renner K.

Cancer Lett. 2019 Feb 1;442:453-463. doi: 10.1016/j.canlet.2018.11.018. Epub 2018 Nov 24.

PMID:
30481565
30.

Arts-Based Research Approaches to Studying Mechanisms of Change in the Creative Arts Therapies.

Gerber N, Bryl K, Potvin N, Blank CA.

Front Psychol. 2018 Nov 1;9:2076. doi: 10.3389/fpsyg.2018.02076. eCollection 2018.

31.

External validation of a prediction model to select the best day-three embryo for transfer in in vitro fertilization or intracytoplasmatic sperm injection procedures.

Blank C, Duijf IT, Slappendel E, Mischi M, Houterman S, Maas JWM, de Sutter P, Schoot BC.

Fertil Steril. 2018 Oct;110(5):917-924. doi: 10.1016/j.fertnstert.2018.06.004.

PMID:
30316438
32.

Influence of dietary zinc concentration and supplemental zinc source on nutrient digestibility, zinc absorption, and retention in sheep.

VanValin KR, Genther-Schroeder ON, Carmichael RN, Blank CP, Deters EL, Hartman SJ, Niedermayer EK, Laudert SB, Hansen SL.

J Anim Sci. 2018 Dec 3;96(12):5336-5344. doi: 10.1093/jas/sky384.

PMID:
30299509
33.

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.

Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, Krijgsman O, van den Braber M, Philips D, Broeks A, van Thienen JV, Mallo HA, Adriaansz S, Ter Meulen S, Pronk LM, Grijpink-Ongering LG, Bruining A, Gittelman RM, Warren S, van Tinteren H, Peeper DS, Haanen JBAG, van Akkooi ACJ, Schumacher TN.

Nat Med. 2018 Nov;24(11):1655-1661. doi: 10.1038/s41591-018-0198-0. Epub 2018 Oct 8.

PMID:
30297911
34.

The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.

van Dijk N, Funt SA, Blank CU, Powles T, Rosenberg JE, van der Heijden MS.

Eur Urol. 2019 Mar;75(3):435-444. doi: 10.1016/j.eururo.2018.09.022. Epub 2018 Sep 28. Review.

PMID:
30274701
35.

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.

Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A.

Eur J Cancer. 2018 Sep;101:236-243. doi: 10.1016/j.ejca.2018.06.034. Epub 2018 Aug 7.

36.

Targeting tumor-associated acidity in cancer immunotherapy.

Lacroix R, Rozeman EA, Kreutz M, Renner K, Blank CU.

Cancer Immunol Immunother. 2018 Sep;67(9):1331-1348. doi: 10.1007/s00262-018-2195-z. Epub 2018 Jul 5. Review.

PMID:
29974196
37.

Community-Driven Data Analysis Training for Biology.

Batut B, Hiltemann S, Bagnacani A, Baker D, Bhardwaj V, Blank C, Bretaudeau A, Brillet-Guéguen L, Čech M, Chilton J, Clements D, Doppelt-Azeroual O, Erxleben A, Freeberg MA, Gladman S, Hoogstrate Y, Hotz HR, Houwaart T, Jagtap P, Larivière D, Le Corguillé G, Manke T, Mareuil F, Ramírez F, Ryan D, Sigloch FC, Soranzo N, Wolff J, Videm P, Wolfien M, Wubuli A, Yusuf D; Galaxy Training Network, Taylor J, Backofen R, Nekrutenko A, Grüning B.

Cell Syst. 2018 Jun 27;6(6):752-758.e1. doi: 10.1016/j.cels.2018.05.012.

38.

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.

Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA.

Ann Oncol. 2018 Aug 1;29(8):1861-1868. doi: 10.1093/annonc/mdy226.

PMID:
29945191
39.

Primum non nocere: earlier cessation of glucose monitoring is possible.

Blank C, van Dillen J, Hogeveen M.

Eur J Pediatr. 2018 Aug;177(8):1239-1245. doi: 10.1007/s00431-018-3169-z. Epub 2018 May 30.

40.

The influence of supplemental zinc and ractopamine hydrochloride on trace mineral and nitrogen retention of beef steers.

Carmichael RN, Genther-Schroeder ON, Blank CP, Deters EL, Hartman SJ, Niedermayer EK, Hansen SL.

J Anim Sci. 2018 Jun 29;96(7):2939-2948. doi: 10.1093/jas/sky177.

PMID:
29733402
41.

The effects of 8 weeks of two different training methods on on-sight lead climbing performance.

Philippe M, Filzwieser I, Leichtfried V, Blank C, Haslinger S, Fleckenstein J, Schobersberger W.

J Sports Med Phys Fitness. 2019 Apr;59(4):561-568. doi: 10.23736/S0022-4707.18.08399-8. Epub 2018 May 2.

PMID:
29722250
42.

Impact of a single, short morning bright light exposure on tryptophan pathways and visuo- and sensorimotor performance: a crossover study.

Schobersberger W, Blank C, Hanser F, Griesmacher A, Canazei M, Leichtfried V.

J Physiol Anthropol. 2018 Apr 23;37(1):12. doi: 10.1186/s40101-018-0173-y.

43.

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C.

N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15.

44.

Injuries in Austrian football players: Are they an issue?

Fischer F, Hoser C, Blank C, Schobersberger W, Hepperger C, Gföller P, Fink C.

Sportverletz Sportschaden. 2019 Mar;33(1):43-50. doi: 10.1055/s-0043-125000. Epub 2018 Mar 12.

PMID:
29529694
45.

Effects of Levetiracetam and Sulthiame on EEG in benign epilepsy with centrotemporal spikes: A randomized controlled trial.

Tacke M, Borggraefe I, Gerstl L, Heinen F, Vill K, Bonfert M, Bast T; HEAD Study group, Neubauer BA, Baumeister F, Baethmann M, Bentele K, Blank C, Blank HM, Bode H, Bosch F, Brandl U, Brockmann K, Dahlem P, Ernst JP, Feldmann E, Fiedler A, Gerigk M, Heß S, Hikel C, Hoffmann HG, Kieslich M, Klepper J, Kluger G, Koch H, Koch W, Korinthenberg R, Krois I, Kühne H, Kurlemann G, Mandl M, Mause U, Navratil P, Opp J, Penzien J, Prietsch V, Quattländer A, Rating D, Schara U, Shamdeen MG, Sprinz A, Wendker-Magrabi H, Stephani U, Muhle H, Straßburg HM, Töpke B, Trollmann R, Tuschen-Hofstätter E, Waltz S, Weber G, Wien FU, Wolff M, Polster T, Freitag H, Sönmez Ö, Reinhardt K, Traus M, Hoovey Z.

Seizure. 2018 Mar;56:115-120. doi: 10.1016/j.seizure.2018.01.015. Epub 2018 Feb 3.

46.

Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.

Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, van Thienen JV, van Leerdam ME, van den Heuvel M, Blank CU, van Dieren J, Haanen JBAG.

ESMO Open. 2018 Jan 13;3(1):e000278. doi: 10.1136/esmoopen-2017-000278. eCollection 2018. Review.

47.

Disseminating Metaproteomic Informatics Capabilities and Knowledge Using the Galaxy-P Framework.

Blank C, Easterly C, Gruening B, Johnson J, Kolmeder CA, Kumar P, May D, Mehta S, Mesuere B, Brown Z, Elias JE, Hervey WJ, McGowan T, Muth T, Nunn B, Rudney J, Tanca A, Griffin TJ, Jagtap PD.

Proteomes. 2018 Jan 31;6(1). pii: E7. doi: 10.3390/proteomes6010007.

48.

Involuntary psychiatric hospitalisation, stigma stress and recovery: a 2-year study.

Xu Z, Lay B, Oexle N, Drack T, Bleiker M, Lengler S, Blank C, Müller M, Mayer B, Rössler W, Rüsch N.

Epidemiol Psychiatr Sci. 2018 Jan 31:1-8. doi: 10.1017/S2045796018000021. [Epub ahead of print]

PMID:
29382403
49.

Involuntary hospitalization, stigma stress and suicidality: a longitudinal study.

Xu Z, Müller M, Lay B, Oexle N, Drack T, Bleiker M, Lengler S, Blank C, Vetter S, Rössler W, Rüsch N.

Soc Psychiatry Psychiatr Epidemiol. 2018 Mar;53(3):309-312. doi: 10.1007/s00127-018-1489-y. Epub 2018 Jan 27.

PMID:
29380026
50.

Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.

Geukes Foppen MH, Boogerd W, Blank CU, van Thienen JV, Haanen JB, Brandsma D.

Melanoma Res. 2018 Apr;28(2):126-133. doi: 10.1097/CMR.0000000000000429.

PMID:
29356790

Supplemental Content

Support Center